MAPT and Alzheimer disease: Collectively, results of these analyses demonstrate the concomitant reduction by APα of four major pathological markers of AD, Aβ, phospho-tau, microglial activation and white matter loss, and provide pre-clinical evidence in support of the efficacy of APα to decrease and delay development of AD pathology.